Headquartered in Hayward, CA Fiscal year ends December NYSE: RCUS arcusbio.com
Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases. Founded in 2015, the company's late-stage pipeline includes casdatifan, a HIF-2α inhibitor being evaluated across multiple lines of therapy in clear cell renal cell carcinoma (ccRCC), and quemliclustat, a small-molecule CD73 inhibitor in a Phase 3 trial for first-line metastatic pancreatic ductal adenocarcinoma. Arcus partners with industry collaborators including Gilead Sciences, Taiho Pharmaceutical, Bristol Myers Squibb, Summit Therapeutics, and AVEO Oncology. The company is also building an immunology portfolio targeting large inflammatory and autoimmune disease markets, including programs for AB102 (oral MRGPRX2 antagonist for atopic dermatitis and chronic spontaneous urticaria), an oral TNF inhibitor, and additional programs targeting CCR6, STAT6, CD89, and CD40L pathways. Arcus trades on the NYSE under the ticker RCUS. Updated
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms. Five biotechs stand out as compelling acquisition candidates, each…
Biotech companies saw the most notable insider purchases of the past week. A Mexican billionaire also continued to build a stake.
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
In a world where investors are starving to find growth, many of the well established biotech leaders and many of the large pharmaceutical companies have been acquiring growth on top of their…
Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases.
The Wall Street consensus 12-month price target for RCUS is $39.91.
